Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-02

Clinical Trial Update: Sitagliptin for the Treatment of Grade 3-4 and Refractory Acute Graft-versus-host Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sitagliptin for grade 3-4 and refractory acute graft-versus-host disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sitagliptin (sitagliptin)

Snippet

Sponsor: Rabin Medical Center | Conditions: Graft Vs Host Disease | Phase 2 | Status: UNKNOWN